Mode
Text Size
Log in / Sign up
N/A N=58 Randomized Double-blind Treatment

Sing for Your Saunter

Parkinson Disease

Enrolled (actual)
58
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Gait Speed — 1.12; 1.17; 1.04; 1.09 meters per second

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Mentally singing (Behavioral); Listening to music (Behavioral)
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
Washington University School of Medicine
Primary completion
Jan 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Gait Speed
1.12; 1.17; 1.04; 1.09; 1.16; 1.11
PRIMARY
Stride Length Variability
.014; .013; .015; .014; .013; .012
SECONDARY
Brain Activity (BOLD Signal)
-.054; -.017; -.053; -.053; .069; .139

Summary

Older adults, and particularly those with Parkinson disease (PD), may experience walking difficulties that negatively impact their daily function and quality of life. This project will examine the impact of music and mentally singing on walking performance, with a goal of understanding what types of rhythmic cues are most helpful. Our pilot work suggests that imagined, mental singing (i.e., singing in your head) while while walking helps people walk faster with greater stability, whereas walking to music also helps people walk faster but with reduced stability. In Aim 1, the investigators will compare walking while mentally singing to walking while listening to music, using personalized cues tailored to each person's walking performance. The investigators hypothesize stride time variability will be less in the mental singing condition compared to listening to music; and that mental singing and listening to music will improve gait speed similarly as compared to the uncued condition. The investigators will also test whether finger tapping, a rhythmic task similar to walking in many ways, responds similarly while mentally singing and listening to music. In Aim 2, the investigator will investigate the brain mechanisms underlying the enhancements in movement performance seen with mental signing or listening to music. The investigators will use magnetic resonance imaging (MRI) to measure brain activity during finger tapping with and without various cues to understand which areas of the brain are more or less responsive to the cues. The investigators hypothesize individuals with PD will exhibit lesser activation of putamen and greater activation of cortical motor areas and cerebellum compared to controls in all tapping conditions; and internal, mental singing during tapping will elicit greater activation of the putamen and lesser activation of cortical motor areas in both groups compared to uncued tapping and tapping while listening to music.

Eligibility Criteria

Inclusion Criteria for all participants:

  • at least 30 years of age;
  • willing and able to provide informed consent;
  • right-handed or ambidextrous;
  • normal hearing;
  • weight less than 250 lbs; and
  • able to walk for 10 continuous minutes independently.

Inclusion criteria for participants with PD also include:

  • diagnosis of idiopathic, typical Parkinson disease according to the United Kingdom Brain Bank Criteria;
  • Hoehn & Yahr stages 2-3 (mild to moderate disease severity);
  • stable on all PD medications for at least 2 months prior to study entry;
  • a score of 1 or less on item # 7 on the New Freezing of Gait Questionnaire; and
  • score of ≥ 1 on the Movement Disorder Society - Unified Parkinson Disease Rating Scale (MDS-UPDRS)-III Item #10 indicating observable gait impairment.

Exclusion Criteria for both groups include:

  • diagnosis of any other neurological condition;
  • significant cognitive impairment;
  • unstable medical or concomitant illnesses or psychiatric conditions which, in the opinion of the investigators, would preclude successful participation;
  • cardiac problems that interfere with ability to safely participate (i.e., uncontrolled congestive heart failure, myocardial infarction in past 6 months, complex cardiac arrhythmias, significant left ventricular dysfunction, dyspnea on exertion, chest pain or pressure, resting tachycardia (>100 beats/min); uncontrolled BP (resting systolic BP >160 mmHg or diastolic BP >100 mmHg));
  • orthopedic problems in the lower extremities or spine that may limit walking (i.e., severe arthritis, spinal stenosis);
  • contraindications for magnetic resonance imaging (e.g., metallic implants); or
  • uncontrolled tremor or dyskinesia (while on PD medications if applicable).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04246476). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search